Investigational compound empagliflozin significantly reduced BG in T2D

In the pooled analysis, presented at the American Diabetes Association 73rd Scientific Sessions, people with T2D treated with empagliflozin versus placebo achieved significant reductions in HbA1c, fasting plasma glucose, weight and blood pressure after 24 weeks (Lilly)